Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/26–06/29 | 06/30 | 504,695 sh6 trades | $21.23avg. | $10,712,549.82 | −34.1% | |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/23–06/25 | 06/26 | 267,760 sh9 trades | $21.09avg. | $5,646,496.8 | −19.9% | |
Lucera ErickCFO | Dyne TherapeuticsDYN | Open-market sale | 06/25 | 06/26 | 2,362 sh | $20.37 | $48,113.94 | −1.9% |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 263,962 sh3 trades | $20.70avg. | $5,464,855.27 | −6.4% | |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/17–06/18 | 06/22 | 84,355 sh2 trades | $20.10avg. | $1,695,626.63 | −2.0% | |
Cox JohnCEO & President | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/16 | 06/17 | 2,683 sh | $18.33 | $49,179.39 | −0.7% |
Kerr DouglasChief Medical Officer | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/16 | 06/17 | 887 sh | $18.33 | $16,258.71 | −0.5% |
Johanna Friedl-NadererChief Commercial Officer | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 06/16 | 06/17 | 145 sh | $18.33 | $2,657.85 | −0.1% |
Brian S. PosnerDirector | Dyne TherapeuticsDYN | Open-market buy | 06/08 | 06/09 | 2,000 sh | $16.94 | $33,880 | +8.9% |
Brian S. PosnerDirector | Dyne TherapeuticsDYN | Open-market buy | 06/03 | 06/05 | 2,500 sh | $17.48 | $43,700 | +12.5% |
Brian S. PosnerDirector | Dyne TherapeuticsDYN | Open-market buy | 05/26 | 05/28 | 2,000 sh | $18.21 | $36,420 | +11.1% |
Brian S. PosnerDirector | Dyne TherapeuticsDYN | Open-market buy | 05/20 | 05/22 | 2,500 sh | $17.12 | $42,800 | +16.1% |
Cox JohnCEO & President | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 05/13 | 05/14 | 3,311 sh | $18.36 | $60,789.96 | −0.9% |
Lucera ErickCFO | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 05/13 | 05/14 | 1,448 sh | $18.36 | $26,585.28 | −1.2% |
Kerr DouglasChief Medical Officer | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 05/13 | 05/14 | 1,564 sh | $18.36 | $28,715.04 | −0.9% |
Johanna Friedl-NadererChief Commercial Officer | Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 05/13 | 05/14 | 228 sh | $18.36 | $4,186.08 | −0.1% |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 05/04–05/06 | 05/06 | 106,723 sh12 trades | $18.14avg. | $1,936,341.42 | −8.6% | |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 04/28 | 04/30 | 227,337 sh8 trades | $18.38avg. | $4,178,516.06 | −16.4% | |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 04/23–04/27 | 04/27 | 384,549 sh12 trades | $18.47avg. | $7,101,119.51 | −24.2% | |
Dyne TherapeuticsDYN | Open-market sale10b5-1 plan | 04/21–04/22 | 04/23 | 10,952 sh2 trades | $20.01avg. | $219,123 | −0.3% |